Caterina Vicentini

High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers.

Clinical application of microRNA testing in neuroendocrine tumors of the gastrointestinal tract.

Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups.

Reporting tumor molecular heterogeneity in histopathological diagnosis.

A differentially expressed set of microRNAs in cerebro-spinal fluid (CSF) can diagnose CNS malignancies.

RASSF1 tumor suppressor gene in pancreatic ductal adenocarcinoma: correlation of expression, chromosomal status and epigenetic changes.

ERK Activation Globally Downregulates miRNAs through Phosphorylating Exportin-5.

Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.

Whole-genome landscape of pancreatic neuroendocrine tumours.

Fhit down-regulation is an early event in pancreatic carcinogenesis.

Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma.

ERG alterations and mTOR pathway activation in primary prostate carcinomas developing castration-resistance.

Mutational and copy number asset of primary sporadic neuroendocrine tumors of the small intestine.

Molecular alterations associated with metastases of solid pseudopapillary neoplasms of the pancreas.

Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations.